PubMed Health⌕ Search

PubMed · 17146155

Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hiroaki Senba, Mikihiko Kawano, Masanobu Kawakami. 2006. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.. https://doi.org/10.5551/jat.13.263

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease.

We have prospectively evaluated the risk of incident coronary events in association with serum total homocysteine in patients with preexisting chronic coronary heart disease. A nested case-control design was used. Total homocysteine concentration was measured in baseline fasting serum samples from patients with chronic coronary heart disease enrolled in the Bezafibrate Infarction Prevention Study (n = 3,090) who developed coronary events during 6.2 years of follow-up (n = 69). They were matched for age and gender with controls without subsequent cardiovascular events. Elevated homocysteine levels were associated with 2.5 times higher risk of subsequent coronary events and each 5 mumol/l increment was associated with a 25% higher risk.

Bezafibrate↗

Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals.

Six antihyperlipidemic agents-bezafibrate, ciprofibrate, clofibrate, clofibric acid, fenofibrate and gemfibrozil were separated by means of capillary electrophoresis, using unmodified fused silica tubing of 75 microm internal diameter and 87 cm length (65 cm to the UV detector at 227 nm). Migration time and selectivity were examined in differing pH of separation buffer, varying separation voltage and differing temperature. Optimal separation was achieved using 1/15 M phosphate buffer pH 10, 240 V/cm at 25 degrees C. The optimal separation conditions were then used to elaborate the method of quantitation of bezafibrate, ciprofibrate and gemfibrozil in Bezamidin, Lipanor and Gemfibral pharmaceuticals. The clofibric acid was used as internal standard. The calibration curve was constructed from 0.2 to 0.8 mg/ml of each compound and 0.5 mg/ml of internal standard. The calibration data were proved to be linear by Mandel and Lack-of-fit tests. Statistical evaluation of results proved proper recovery of elaborated method (102.42, 97.32 and 101.51%, respectively) and good repeatability (9.51, 5.52 and 11.15%, respectively). The linearity of recovery was also tested by analyzing increasing amount of the samples. Three fortified samples of each drug were also analyzed to perform additional accuracy validation.

Bezafibrate↗